Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of s mall m olecule GLP-1 receptor ( GLP-1R) a gonist ASC30 in 65 participants...
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a...
From Test Drive to Co-Creation -- The 2025 Chery International User Summit Builds a New Mobility Ecosystem
WUHU, China, Oct. 19, 2025 /PRNewswire/ -- From October 17 to 21, under the theme "Co-Create • Co-Define," the 2025 Chery International User Summit gathered 1,200 guests from over 100 countries and regions in Wuhu. The event offered an immersive...
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3...
From "Wheels" to a "Three-Dimensional Ecosystem": The 2025 Chery Global Innovation Conference Unveils a New Blueprint for Intelligent Mobility
WUHU, China, Oct. 18, 2025 /PRNewswire/ -- A clear and composed "Hello everyone, I'm Mornine" ignited the climax of the 2025 Chery Global Innovation Conference. This unique "presenter" was none other than AiMOGA robot Mornine. In a ten-minute fully...
KLN Wins GBA Excellence in Logistics Solutions Award at the Hong Kong Economic Journal GBA Brand Awards of Excellence 2025
HONG KONG, Oct. 17, 2025 /PRNewswire/ -- KLN Logistics Group Limited ("KLN"; Stock Code 0636.HK) has won the title of GBA Excellence in Logistics Solutions Award at the Hong Kong Economic Journal GBA Brand Awards of Excellence 2025 (the 'Awards'),...
Amazon sets new GUINNESS WORLD RECORDS® for Gen AI Apps with schools in West Java
GUINNESS WORLD RECORDS title set for "Most Applications Made In An On-site Generative AI Event" JAKARTA, Indonesia, Oct. 17, 2025 /PRNewswire/ -- Amazon, together with teachers and students across 21 high schools in West Java, Indonesia made history...
BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria
Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 26, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) of China's...
BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions
Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes and overweight, non-obese individuals Preclinical data for BGM1812 supports...
Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions
In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions...